Hopital Principal de Dakar Senegal Report issue

Academic/Hospital Phase 3

Organization Overview

First Clinical Trial
2005
NCT00120796
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2005

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (2)

hepatitis b vaccine (recombinant) (recombivax) (1 trial)

lamivudine (epivir) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Hepatitis (Phase 3)

Hepatitis A (Phase 3)

Hepatitis B (Phase 3)

Hepatitis B, Chronic (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 2